立体定向体部放疗治疗中央型肺肿瘤的可行性和疗效。

The feasibility and efficacy of stereotactic body radiotherapy for centrally-located lung tumors.

机构信息

Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan.

出版信息

Anticancer Res. 2013 Nov;33(11):4959-64.

PMID:24222136

Abstract

AIM

To investigate the toxicity and outcome of stereotactic body radiotherapy (SBRT) for centrally-located lung tumors.

PATIENTS AND METHODS

A retrospective review was conducted in 45 consecutive patients with centrally-located lung tumors who underwent SBRT. The incidence rate of adverse events (AEs) and outcome after SBRT for primary (32 patients), metastatic and recurrent (13 patients) lung tumors were evaluated.

RESULTS

The median follow-up period was 21.2 months. Except for one patient who had grade 4 gastrointestinal toxicity, no patient exhibited any grade 4-5 AE. The 2-year overall survival of patients with primary non-small cell lung cancer (NSCLC) was significantly better than that of those with metastatic and recurrent tumors of 69.4% vs. 46.9% (p=0.04). The local control rates at two years, for patients in the NSCLC and the metastatic/recurrent groups were 70.9% and 100%, respectively (p=0.98).

CONCLUSION

SBRT provided effective treatment for centrally-located lung tumors with tolerable toxicity.

摘要

目的

探讨立体定向体部放疗（SBRT）治疗中央型肺部肿瘤的毒性和结果。

患者与方法

对 45 例接受 SBRT 治疗的中央型肺部肿瘤患者进行回顾性分析。评估 SBRT 治疗原发性（32 例）、转移性和复发性（13 例）肺部肿瘤后的不良事件（AE）发生率和结果。

结果

中位随访时间为 21.2 个月。除 1 例患者出现 4 级胃肠道毒性外，无患者出现 4-5 级 AE。原发性非小细胞肺癌（NSCLC）患者的 2 年总生存率明显优于转移性和复发性肿瘤患者（69.4% vs. 46.9%，p=0.04）。NSCLC 和转移性/复发性肿瘤患者的 2 年局部控制率分别为 70.9%和 100%（p=0.98）。